Cargando…

Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria

BACKGROUND AND PURPOSE: Randomized controlled trials and observational studies of nabiximols oromucosal spray in patients with multiple sclerosis (MS) spasticity have shown improvement in a range of associated symptoms (pain, spasms, fatigue, bladder dysfunction, and sleep disturbances). This study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guger, Michael, Hatschenberger, Robert, Leutmezer, Fritz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097150/ https://www.ncbi.nlm.nih.gov/pubmed/36934456 http://dx.doi.org/10.1002/brb3.2947

Ejemplares similares

A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols
por: Chisari, Clara Grazia, et al.
Publicado: (2023)

Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity
por: Gajofatto, Alberto, et al.
Publicado: (2023)

Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
por: D’hooghe, Marie, et al.
Publicado: (2021)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’
por: Patti, Francesco, et al.
Publicado: (2022)

Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis
por: Novarella, Federica, et al.
Publicado: (2022)

Leg Spasticity and Ambulation in Multiple Sclerosis
por: Balantrapu, Swathi, et al.
Publicado: (2014)

Oral therapies for treatment of relapsing–remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method
por: Guger, Michael, et al.
Publicado: (2020)

Spasticity, spastic dystonia, and static stretch reflex in hypertonic muscles of patients with multiple sclerosis
por: Puce, Luca, et al.
Publicado: (2021)

Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria
por: Guger, Michael, et al.
Publicado: (2022)

Cannabinoids in the management of spasticity associated with multiple sclerosis
por: Malfitano, Anna Maria, et al.
Publicado: (2008)

Dry needling for treating spasticity in multiple sclerosis
por: del Pilar Pérez-Trujillo, María, et al.
Publicado: (2021)

Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing–remitting multiple sclerosis in Austria
por: Guger, Michael, et al.
Publicado: (2023)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Functional intermuscular reduction in spasticity for people with multiple sclerosis
por: Miller, Bobbette J, et al.
Publicado: (2022)

Clinical insights on the spasticity-plus syndrome in multiple sclerosis
por: Alami Marrouni, Kanza, et al.
Publicado: (2022)

Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)

Real‐life use of oral disease‐modifying treatments in Austria
por: Guger, Michael, et al.
Publicado: (2019)

Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)

The Coexistence of Multiple Sclerosis and Hereditary Spastic Paraparesis in a Patient
por: Yazıcı, Işıl, et al.
Publicado: (2013)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

Isolated Trapezius Strain in a Patient with Multiple Sclerosis and Spasticity
por: Wang, Eric C., et al.
Publicado: (2015)

The Broad Concept of “Spasticity-Plus Syndrome” in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms
por: Fernández, Óscar, et al.
Publicado: (2020)

Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat(®) Methodology
por: Fernandez, Oscar, et al.
Publicado: (2021)

New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids
por: Smith, Paul F
Publicado: (2010)

Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation
por: Russo, Margherita, et al.
Publicado: (2015)

The Effect of Repetitive Transcranial Magnetic Stimulation on Spasticity in Patients with Multiple Sclerosis
por: Şan, Ayça Uran, et al.
Publicado: (2019)

Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple Sclerosis
por: Bruno, Antonio, et al.
Publicado: (2022)

Evaluation of the Multiple Sclerosis Spasticity Scale 88: A Short Report
por: Freeman, Jenny, et al.
Publicado: (2019)

Perceived Impact of Spasticity Is Associated with Spatial and Temporal Parameters of Gait in Multiple Sclerosis
por: Balantrapu, Swathi, et al.
Publicado: (2012)

Validation of the Serbian Version of Multiple Sclerosis Spasticity Scale 88 (MSSS-88)
por: Rodic, Sindi Z., et al.
Publicado: (2016)

Early development of spasticity following stroke: a prospective, observational trial
por: Wissel, Jörg, et al.
Publicado: (2010)

Spastic Constipation
Publicado: (1906)

The Spastic Colon
por: Smith, David
Publicado: (1936)

Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay without Spasticity
por: Aida, Izumi, et al.
Publicado: (2021)

Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis
por: Birke, Rüdiger, et al.
Publicado: (2022)

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review
por: Lakhan, Shaheen E, et al.
Publicado: (2009)

Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany
por: Henze, Thomas, et al.
Publicado: (2014)

Goal-Setting in Multiple Sclerosis-Related Spasticity Treated with Botulinum Toxin: The GASEPTOX Study
por: Baccouche, Ines, et al.
Publicado: (2022)

Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial
por: Okuda, Darin T, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_em2tu054fns057jeqqip8e6h3h